Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 6/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26912212 | 0.80 | MEN1 (0.40) | BRD4RAPGEF4L3MBTL1HTR6MEN1 | |
| SCHEMBL26913094 | 0.79 | ALDH1A1 (0.39) | BRD4RAPGEF4L3MBTL1HTR6MEN1 | |
| SCHEMBL26912343 | 0.79 | BRD4 (0.38) | BRD4RAPGEF4L3MBTL1HTR6MEN1 | |
| SCHEMBL26912286 | 0.78 | CFD (0.45) | BRD4KDM4EHTR6MEN1KMT2A | |
| SCHEMBL26912847 | 0.78 | BRD4 (0.35) | BRD4RAPGEF4L3MBTL1HTR6PKM | |
| SCHEMBL26913012 | 0.78 | BRD4 (0.35) | BRD4RAPGEF4L3MBTL1KDM4ECA1 | |
| SCHEMBL26912221 | 0.78 | BRD4 (0.40) | BRD4RAPGEF4L3MBTL1KDM4ECA1 | |
| SCHEMBL26912926 | 0.78 | CA1 (0.42) | BRD4RAPGEF4L3MBTL1KDM4EUBE2N | |
| SCHEMBL26912207 | 0.75 | POLB (0.35) | BRD4L3MBTL1CA1CA2PKM | |
| SCHEMBL26913270 | 0.74 | PPARG (0.43) | BRD4RAPGEF4HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | BRD4 1185/4885RAPGEF4 907/4885L3MBTL1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.